



Integra LifeSciences Announces Acquisition of Omni-Tract Surgical

PLAINSBORO, N.J., Jan 9, 2009 (GlobeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it has acquired Minnesota Scientific, Inc. (d/b/a Omni-Tract Surgical).

Omni-Tract Surgical, based in St. Paul, MN, is a global leader in the development and manufacture of table mounted retractors. Omni-Tract markets and sells these systems for use in vascular, bariatric, general, urologic, orthopedic, spine, pediatric, and laparoscopic surgery. Integra expects to maintain Omni-Tract's operations in Minnesota and will integrate Omni-Tract's product lines into its combined offering of JARIT(R), Padgett(TM), R&B Redmond(TM), and Luxtec(R) lines of surgical instruments and illumination systems sold by the Integra Surgical sales team.

"We are excited about the opportunities for our newly expanded retractor business," said Robert Perrett, President of the Integra Medical Instrument Group. "We see the potential for considerable synergies from the combination of the product development, manufacturing and distribution businesses within the Integra Surgical business. We will now be able to offer more products through the Integra Surgical sales channel for our hospital customers to meet their changing needs in the operating room and sterile processing department. Simply stated, 'More through Integra Surgical.'"

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of clinically relevant, innovative and cost-effective surgical implants and medical instruments. The company's products are used to treat millions of patients every year, primarily in neurosurgery, orthopedics and general surgery. Integra's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. Please visit our website at (<http://www.Integra-LS.com>).

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning expectations for the strategic benefits that this acquisition will provide to Integra. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, Integra's ability to successfully integrate the Minnesota Scientific business into its own operations could affect the extent of the strategic benefits that Integra generates from this acquisition. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2007 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART-A

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation

John B. Henneman, III, Executive Vice President,
Finance and Administration, and Chief Financial Officer
(609) 936-2481
jhenneman@Integra-LS.com

Karen Mroz-Bremner, Senior Manager, Corporate Development
and Investor Relations
(609) 936-6929
karen.mroz-bremner@integra-LS.com

(C) Copyright 2008 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX